Lagging CDER Review Divisions Could Learn From Oncology, Antiviral Offices
FDA’s drugs center should identify “best practices” in oncology and antiviral drug reviews that could be applied by less efficient review divisions, such as cardio/renal and neurology, authors of a Manhattan Institute report say.
You may also be interested in...
Agency reports preventable deficiencies, including failure to select optimal drug doses and suitable study endpoints, account for many drug rejections, approval delays.
FDA official says the rate of approving applications in the first review cycle may not increase much more, even as the new review model, intended to promote more first-cycle approvals, has yet to finish with its inaugural applications.
Presidential advisory panel makes eight recommendations to improve innovation in drug discovery, development and evaluation; calls for broad partnership of stakeholders to accelerate therapeutics, $40 million annual appropriations for FDA’s Sentinel System.